PCI Biotech Holding ASA (4QG)

Overview

PCI Biotech Holding ASA is a pioneering biopharmaceutical company, established in 2007 and headquartered in Oslo, Norway. It specializes in creating innovative cancer treatments using its proprietary photochemical internalization (PCI) technology platform. This platform is at the core of its research and development efforts, aiming to introduce new therapeutic paradigms in the fight against cancer. Through both in-house development and strategic partnerships, PCI Biotech aspires to transform cancer care, focusing on a pipeline that includes chemotherapeutics, therapeutic vaccination, and nucleic acid therapeutics delivery technology. The company collaborates with several organizations, including Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum, to enhance its research capabilities and expand the applicability of its technologies.

Products and Services

• fimaCHEM

  A chemotherapeutic approach designed for the treatment of cancer. Utilizing PCI Biotech’s proprietary PCI technology, fimaCHEM enhances the effect of chemotherapeutic agents, aiming to improve outcomes for patients with difficult-to-treat cancers. This innovation represents the company's commitment to addressing the limitations of current cancer treatments by facilitating more effective drug delivery to cancerous cells.

• fimaVACC

  This T-cell induction technology is geared towards therapeutic vaccination, currently in the pre-clinical study phase. fimaVACC is designed to potentiate the immune system's ability to fight cancer by enhancing the activation and proliferation of T-cells, which are crucial for immune response. By improving the efficacy of therapeutic vaccines, PCI Biotech aims to offer a novel solution for increasing the immunogenicity of cancer vaccines, potentially transforming cancer therapy.

• fimaNAc

  A nucleic acid therapeutics delivery technology in the pre-clinical study phase. fimaNAc aims to solve one of the main challenges in nucleic acid-based therapies: efficient and targeted delivery into cells. By facilitating the delivery of nucleic acid therapeutics, such as small interfering RNA (siRNA) or mRNA, directly to affected cells, PCI Biotech is paving the way for advanced treatments for cancer and other diseases that can be addressed through genetic intervention.

• Amphinex

  Known also as fimaporfin, Amphinex is a photosensitizer used in combination with the company’s PCI technology. It plays a critical role in the activation of the PCI process, enabling precise delivery and activation of therapeutic agents within cancer cells. This specificity not only enhances the treatment's potency but also reduces the risk of adverse side effects, demonstrating the potential of PCI technology in improving patient care.